Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 17,932 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nutritional and Metabolic Disease Clear all
Completed Not applicable Interventional

A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir

NCT00002251
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Studying the Effects of Phentermine on Eating Behavior

NCT01886937
View directory record Official record
Conditions
Obesity
Interventions
Phentermine, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 16, 2026, 9:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Enrolling by invitation Not applicable Interventional

Prevention of Injury in Skilled Nursing Facilities Through Optimizing Medications

NCT06304428
View directory record Official record
Conditions
Accidental Falls/Prevention and Control, Osteoporosis
Interventions
Deprescribing Care Model, Bone Health Service Model, Injury Prevention Service Model
Other
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
3,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Recruiting Phase 1 Interventional

Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies

NCT06683365
View directory record Official record
Conditions
Multiple System Atrophy, Parkinsons Disease
Interventions
Sural Nerve Graft to the Substantia Nigra, Sham surgery
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional

Watermelon Supplementation and Arterial Stiffness

NCT01185041
View directory record Official record
Conditions
Hypertension
Interventions
Watermelon Extract
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 16, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker

NCT01582139
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Heart rate informed SSM+HMM
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

NCT05583877
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes BOOST, Usual Care
Behavioral
Lead sponsor
Daniel Amante
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass

NCT00394212
View directory record Official record
Conditions
Obesity
Interventions
Transoral Suturing, Sham Endoscopy
Device · Other
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

NCT00065312
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
naveglitazar
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 16, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fabry Screening Study

NCT01019629
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,724 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

Evaluating the Effectiveness of a Community Exercise Program to Reduce the Risk of Metabolic Syndrome Among Black Americans

NCT00783445
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Community-Based Exercise Program (C-FIT), Self-Help Exercise Program (HOME)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

NCT02478775
View directory record Official record
Conditions
Obesity, Fertility
Interventions
Degarelix (GnRH antagonist), recombinant FSH, Cetrorelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exendin-9,39 and Satiety After Bariatric Surgery

NCT02779075
View directory record Official record
Conditions
Obesity
Interventions
Saline, Exendin-9,39
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View directory record Official record
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 16, 2026, 9:22 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease

NCT02337257
View directory record Official record
Conditions
Periodontal Disease, Vitamin D Deficiency
Interventions
Cholecalciferol, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 16, 2026, 9:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Cognitive Assessment by BoCA

NCT04114994
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia, Parkinson Disease, Multiple Sclerosis, TBI
Interventions
Boston Cognitive Assessment (BoCA)
Diagnostic Test
Lead sponsor
Alzheimer's Light LLC
Industry
Eligibility
50 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous mesenchymal stem cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 16, 2026, 9:22 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

NCT01455922
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, glimepiride
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 16, 2026, 9:22 AM EDT
Completed No phase listed Observational

Laparoscopic Revision From Biliopancreatic Diversion to Gastric Bypass

NCT01041456
View directory record Official record
Conditions
Metabolic and Nutritional Complications, Protein Malnutrition, Intestinal Malabsorptive Syndrome, Metabolic Bone Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2010 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurotrophic Indicators of Cognition, Executive Skills, Plasticity, and Adverse Childhood Experiences Study

NCT04076722
View directory record Official record
Conditions
Weight Loss, Wait-List Control
Interventions
Stress reactivity stimuli
Behavioral
Lead sponsor
Oklahoma State University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

NCT03095651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 16, 2026, 9:22 AM EDT